Unknown

Dataset Information

0

FZD10-targeted α-radioimmunotherapy with 225 Ac-labeled OTSA101 achieves complete remission in a synovial sarcoma model.


ABSTRACT: Synovial sarcomas are rare tumors arising in adolescents and young adults. The prognosis for advanced disease is poor, with an overall survival of 12-18 months. Frizzled homolog 10 (FZD10) is overexpressed in most synovial sarcomas, making it a promising therapeutic target. The results of a phase 1 trial of β-radioimmunotherapy (RIT) with the 90 Y-labeled anti-FZD10 antibody OTSA101 revealed a need for improved efficacy. The present study evaluated the potential of α-RIT with OTSA101 labeled with the α-emitter 225 Ac. Competitive inhibition and cell binding assays showed that specific binding of 225 Ac-labeled OTSA101 to SYO-1 synovial sarcoma cells was comparable to that of the imaging agent 111 In-labeled OTSA101. Biodistribution studies showed high uptake in SYO-1 tumors and low uptake in normal organs, except for blood. Dosimetric studies showed that the biologically effective dose (BED) of 225 Ac-labeled OTSA101 for tumors was 7.8 Bd higher than that of 90 Y-labeled OTSA101. 90 Y- and 225 Ac-labeled OTSA101 decreased tumor volume and prolonged survival. 225 Ac-labeled OTSA101 achieved a complete response in 60% of mice, and no recurrence was observed. 225 Ac-labeled OTSA101 induced a larger amount of necrosis and apoptosis than 90 Y-labeled OTSA101, although the cell proliferation decrease was comparable. The BED for normal organs and tissues was tolerable; no treatment-related mortality or obvious toxicity, except for temporary body weight loss, was observed. 225 Ac-labeled OTSA101 provided a high BED for tumors and achieved a 60% complete response in the synovial sarcoma mouse model SYO-1. RIT with 225 Ac-labeled OTSA101 is a promising therapeutic option for synovial sarcoma.

SUBMITTER: Sudo H 

PROVIDER: S-EPMC8819345 | biostudies-literature | 2022 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications

FZD10-targeted α-radioimmunotherapy with <sup>225</sup> Ac-labeled OTSA101 achieves complete remission in a synovial sarcoma model.

Sudo Hitomi H   Tsuji Atsushi B AB   Sugyo Aya A   Harada Yosuke Y   Nagayama Satoshi S   Katagiri Toyomasa T   Nakamura Yusuke Y   Higashi Tatsuya T  

Cancer science 20211221 2


Synovial sarcomas are rare tumors arising in adolescents and young adults. The prognosis for advanced disease is poor, with an overall survival of 12-18 months. Frizzled homolog 10 (FZD10) is overexpressed in most synovial sarcomas, making it a promising therapeutic target. The results of a phase 1 trial of β-radioimmunotherapy (RIT) with the <sup>90</sup> Y-labeled anti-FZD10 antibody OTSA101 revealed a need for improved efficacy. The present study evaluated the potential of α-RIT with OTSA101  ...[more]

Similar Datasets

| S-EPMC7696055 | biostudies-literature
| S-EPMC6343144 | biostudies-literature
| S-EPMC7546012 | biostudies-literature
| S-EPMC10484829 | biostudies-literature
| S-EPMC10728013 | biostudies-literature
| S-EPMC9688344 | biostudies-literature
| S-EPMC10241010 | biostudies-literature
| S-EPMC8688611 | biostudies-literature
| S-EPMC11527918 | biostudies-literature
| S-EPMC10146019 | biostudies-literature